ahlam1399
03-16-2016, 07:52 PM
UK cost agency rejects Amgen?s virus-based cancer drug
LONDON (Reuters) - A first-in-class mela**ma drug from Amgen based on a tumor-killing virus has been deemed **t worth using on Britain's state health service by the country's cost-effectiveness agency NICE.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e4ed38a/sc/13/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=U3n3l-yxU00:EfCfs-Lm8qs:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=U3n3l-yxU00:EfCfs-Lm8qs:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=U3n3l-yxU00:EfCfs-Lm8qs:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=U3n3l-yxU00:EfCfs-Lm8qs:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=U3n3l-yxU00:EfCfs-Lm8qs:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/U3n3l-yxU00
LONDON (Reuters) - A first-in-class mela**ma drug from Amgen based on a tumor-killing virus has been deemed **t worth using on Britain's state health service by the country's cost-effectiveness agency NICE.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e4ed38a/sc/13/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=U3n3l-yxU00:EfCfs-Lm8qs:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=U3n3l-yxU00:EfCfs-Lm8qs:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=U3n3l-yxU00:EfCfs-Lm8qs:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=U3n3l-yxU00:EfCfs-Lm8qs:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=U3n3l-yxU00:EfCfs-Lm8qs:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/U3n3l-yxU00